Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

atnahs pharma netherlands b.v. - olsalazinnatrium - kapsler, hårde - 250 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - olsalazinnatrium - tabletter - 500 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - doxorubicinhydrochlorid - koncentrat til infusionsvæske, opløsning - 2 mg/ml

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - sulfasalazin - tabletter - 500 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - sulfasalazin - enterotabletter - 500 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - hidradenitis suppurativa; psoriasis; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; arthritis, psoriatic - immunosuppressiva - rheumatoid arthritishalimatoz in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. behandling af svær, aktiv og progressiv reumatoid artritis hos voksne, der ikke tidligere er behandlet med methotrexat. halimatoz kan gives som monoterapi i tilfælde af intolerance overfor methotrexat eller når fortsatte behandling med methotrexat er upassende. adalimumab har vist sig at reducere hastigheden af progressionen af ledskader, som målt ved hjælp af x-ray, og til at forbedre den fysiske funktion, når det gives i kombination med methotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritishalimatoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). halimatoz kan gives som monoterapi i tilfælde af intolerance overfor methotrexat eller når fortsatte behandling med methotrexat er upassende (for effekten i monoterapi se afsnit 5. adalimumab er ikke blevet undersøgt hos patienter i alderen mindre end 2 år. enthesitis-related arthritishalimatoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritisankylosing spondylitis (as)halimatoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. aksial spondyloarthritis uden radiografisk evidens for ashalimatoz er indiceret til behandling af voksne med svære aksial spondyloarthritis uden radiografisk evidens for, men med objektive tegn på inflammation med forhøjede crp og / eller mr-scanning, som har haft et utilstrækkeligt svar på, eller er intolerante over for non-steroide anti-inflammatoriske lægemidler. psoriasis arthritishalimatoz er indiceret til behandling af aktiv og progressiv psoriasis arthritis hos voksne, når de svar på tidligere sygdomsmodificerende anti-reumatiske medicinsk behandling har været mangelfuld. adalimumab har vist sig at reducere hastigheden af progressionen af perifere ledskader, som målt ved hjælp af x-ray i patienter med polyartikulær symmetrisk undertyper af sygdommen og til at forbedre den fysiske funktion. psoriasishalimatoz er indiceret til behandling af moderat til svær kronisk plaque psoriasis hos voksne patienter, der er kandidater til systemisk terapi. paediatric plaque psoriasishalimatoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)halimatoz er indiceret til behandling af aktiv moderat til svær hidradenitis suppurativa (acne inversa) hos voksne og unge fra 12 år med et utilstrækkeligt respons på konventionelle systemisk hs-terapi. crohns diseasehalimatoz er indiceret til behandling af moderat til svær aktiv crohns sygdom hos voksne patienter, som ikke har reageret på trods af en fuld og dækkende løbet af behandling med binyrebarkhormon og / eller en iltning, eller der er intolerante over for eller har medicinske kontraindikationer for sådanne behandlinger. paediatric crohn's diseasehalimatoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis/ uveitis/ paediatric uveitisfor full indication see 4.

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - sulfasalazin - tabletter - 500 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tillotts pharma ab - mesalazin - enterotabletter - 400 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - mesalazin - enterotabletter - 400 mg